1. Asthma and Atopic Comorbidities

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States

3. Implications of the Atopic March on Practice

4. Allergic Sensitization and Allergic Diseases

5. Factors Associated With Atopic March

6. Epidemiology in Pediatric Population

7. Epidemiology in Pediatric Population (cont)

8. Examining Progression of Atopic March Classical or Heterogeneous?

9. Pathophysiology of Atopic March

10. What About EoE?

11. The Role of Asthma

12. Asthma As A Heterogeneous Disease How Can We Classify Patients?

13. Asthma As A Heterogeneous Disease How Can We Classify Patients? (cont)

14. A Closer Look at Pathways

15. Antigen Responsiveness at Early Age Indicates Risk of Later Disease

16. Consider the Limitations of the Atopic March

17. Understanding Disease Progression and Prophylaxis

18. Prophylaxis of Atopic March Which Potential Pathways to Block?

19. Is Early Intervention Effective?

20. Halting the Atopic March PAT Study

21. Halting the Atopic March SAM Study

22. SAM Study Results

23. Looking Forward Potential Treatment Options

24. Concluding Remarks

25. Abbreviations